RARE241220C40000
- 12.60
- 0.000.00%
Ultragenyx Pharmaceutical Newsroom
Ultragenyx Pharmaceutical Analyst Ratings
J.P. Morgan Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $102
Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity
Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $70
CCORF Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $121
TD Cowen Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $73
Stifel Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $127
TD Cowen Remains a Buy on Ultragenyx Pharmaceutical (RARE)
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $70 to $135
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Henry Schein (HSIC) and McKesson (MCK)
Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity
RBC Capital Reiterates Outperform on Ultragenyx Pharmaceutical, Maintains $77 Price Target
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $64 to $135
Ultragenyx Pharmaceutical (RARE) Receives a Buy From Cantor Fitzgerald
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), NeoGenomics (NEO) and Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical: Promising Clinical Pipeline and Strong Growth Prospects Justify Buy Rating
Piper Sandler Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $135
Ultragenyx Pharmaceutical (RARE) Gets a Buy From Piper Sandler
Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $116 Price Target
Ultragenyx Pharma Is Maintained at Buy by TD Cowen